Back to Studies

Study analysis · Obesity · 2022

Surgery beats drugs by 50 pounds for weight loss, but for blood sugar? They're tied.

Weight loss surgery leads to about 50 pounds more weight loss than GLP-1 drugs like Ozempic, but both lower blood sugar about the same amount.

Reading level
Low certainty
Level 2a · Systematic review of cohort studiesAssociation, not causationNo causal claims

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study is like a summary of many studies that compared two ways to lose weight: medicine (GLP-1) and surgery. The summary shows that surgery usually leads to more weight loss, but we cannot say for sure that surgery causes more weight loss because some of the studies were not experiments where people were randomly assigned to each group.

What’s the bottom line?

This study looked at all available research comparing weight loss from bariatric surgery and from GLP-1 drugs (like semaglutide).

How strong is this study?

The researchers did a good job by searching for all relevant studies and checking their quality, but only 6 studies were found with a total of 332 people, which is a small number. Also, not all studies were randomized controlled trials, so the results might be biased. Because of this, we should be careful about trusting the exact numbers.

Reporting

40 / 100

  • COI disclosure+40/40
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

20 / 100

  • Randomizationrandomization unclear
  • Blindingblinding unclear
  • Control groupno control group
  • Sample size (n=332)+16.2/20
  • Follow-upno follow-up reported
Publication

100 / 100

Statistical

77 / 100

  • P-values+15/15
  • Effect size+20/20
  • Confidence intervals+15/15
  • Pre-registrationnot pre-registered

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Reviews of Cohort Studies
Level 2a
54

54 / 100

Probability of being correct

Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.

This design cannot establish causation — the findings describe an association, not a cause. This review includes both RCTs and observational studies, and the observational studies are prone to confounding. The small number of studies (6) and potential biases prevent establishing a causal relationship.

No Conflicts

No conflicts of interest identified

Disclosed

No conflicts identified.

Funders

Clinician Investigator Program, University of Toronto

The authors declared no conflicts of interest. Funding from an academic program.

Key takeaways

  1. 01

    Surgery led to about 22.7 kg (50 lbs) more weight loss than the drugs.

  2. 02

    That's a big difference—enough to matter for someone's health.

Surprising findings

  • GLP-1 agonists achieve similar blood sugar control as bariatric surgery, despite far less weight loss.Conventional wisdom holds that weight loss drives glycemic improvement. This suggests GLP-1 drugs have direct glucose-lowering effects independent of weight.
  • Observational studies show a slightly larger weight loss gap (-25.1 kg) than RCTs (-22.7 kg), the opposite of what you'd expect.Usually, real-world data (observational) show smaller effects than tightly controlled trials. Here, the real-world advantage for surgery is bigger, possibly because patients stick with surgery better than daily injections.

Practical takeaways

If weight loss is your primary goal, bariatric surgery is far more effective (50+ lbs more). If diabetes control is the priority, GLP-1 drugs may be sufficient.

The comparison is based on only 332 patients; individual results vary. Side effects, cost, and patient preference matter enormously.

medium confidence

For content creators: don't frame this as 'drugs fail vs. surgery wins.' The nuanced take is 'different tools for different goals.'

The glycemic data comes from only one observational study – not robust. Future research may change the story.

medium confidence

Why this study matters

The Weight Loss Showdown: Surgery Wins by a Landslide

In head-to-head trials, bariatric surgery led to an average of 22.7 kg (about 50 lbs) more weight loss than GLP-1 receptor agonists. That's the difference between 'needing medication' and 'needing a new wardrobe.'

For the average person struggling with obesity, this number makes the choice stark: surgery offers dramatically more weight loss, but it's also more invasive and costly.

Blood Sugar Surprise: It's a Dead Heat

Despite the huge gap in weight loss, glycemic control (measured by HbA1c) was nearly identical: surgery lowered HbA1c by 1.28% more than drugs, but the difference wasn't clinically meaningful. Both dropped it by about 2-3 percentage points from baseline.

This shocks many people who assume more weight loss automatically means better diabetes control. It suggests GLP-1 drugs directly improve blood sugar beyond just weight loss.

The Evidence is Skinny: Only 332 Patients

The meta-analysis included just 6 studies with a total of 332 patients. That's a tiny sample for such a big conclusion. Most studies followed patients for less than a year, and only one looked at long-term glycemic outcomes.

With obesity drugs like semaglutide exploding in popularity, people need to know the data foundation is shaky. It's a reminder that 'best available evidence' doesn't mean 'great evidence.'

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.